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REGULATORY CHALLENGES OF
CONTINUOUS BIOMANUFACTURING

Andy Papas, PhD, MBA
Vice President of Regulatory Affairs
NSF Pharma Biotech Consulting

Agenda
Regulatory Challenges/Considerations

•
•
•
•
•
•

Myth – batch definition challenge
With new approaches and emerging technologies, engage FDA
early and often
With changing regulatory environment –need internal
alignment first
With legacy unique processes or products – embrace education
of agency and re‐education of agency reviewers
Case study ‐ validation of hybrid continuous biomanufacturing
process
Conclusions
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Myth – Batch Definition Challenge
•
•
•
•

Many batch CFR requirements – especially batch
traceability to product defect or recall delineation
Fed‐batch process results in easily identifiable discrete
unit
On first appearance, continuous manufacturing of drugs
– either drug product* or drug substance, doesn’t lend
itself to easily identifiable discrete unit
However, batch can be defined by time or mass interval,
resulting in discrete unit of time or mass, according to
FDA

*FDA recently approved first continuous drug product manufacturing (Orkambi®) in 2015 based on
time‐based interval
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Regulatory Challenges/Considerations
• With new approaches and emerging technologies,
engage FDA early and often
 Facility‐wide rapid microbiological testing for bioburden
control
 New biotech facility designed for all disposable
technology
 First commercial fully integrated continuous
biomanufacturing with PAT
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Regulatory Challenges/Considerations

•

With changing regulatory environment – need
internal alignment first
 Almost always, regulatory environment changes add
more requirements over time
 Fortunately some recent agency adaptive thinking (ICH
Q9 ‐ risk based assessment)
 People set expectations based on prior experiences
• Prior experiences fixed in time
• Time moves on, hard to stay current with agency expectations
• Regulatory affairs chartered to follow current agency thinking
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Educating New Agency Reviewers
• Agency reviewers typically well versed on
mainstream practices but vary in exposure to unique
systems or approaches
 Ex., biologic/device combination product in 1990’s

• In agency meetings, submissions, RTQ, etc. anticipate
to educate new reviewers on products history and on
characteristics of unique system
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Case Study

•

Legacy Perfusion Process
 Labile product produced by hybrid continuous
perfusion upstream process followed by discrete
downstream process
 Process evolution
• Early stage to commercialization scale‐up
• Later scale‐up for additional capacity
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Clinical Manufacturing
Process
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Extensive
analytical
characterization

Scale Up for Commercial Capacity
Criteria
• Triple capacity
• Demonstrate CMC comparability (ICH Q5E)
• Avoid non‐clinical/clinical comparability studies
• For chronic treatment, switch to scale‐up material in
extension studies to evaluate safety
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Drug substance

Extensive
analytical
characterization

bioreactor

Continuous
perfusion for
3 months

bioreactor

Continuous
perfusion for
3 months

Harvest tank
Over 7 days

Staggered 3
weeks

Commercial
Process
Option 2

Continuous
perfusion for
3 months

bioreactor

Harvest tank
Over 7 days
Harvest tank
over 7 days

Clarification
Clarification
Clarification

Pooling
Staggered startup

Column 1, pooled harvests to reach target load
Limited analytical
characterization
Column 2, pooled column 1 eluants to reach target load

Column n, pooled column 2 eluants to reach target load

Drug substance

© NSF 2015 Intl.

11

Extensive analytical characterization

Comparison
Option 2 – Shared Downstream

Option 1 – Three Parallel Streams

PROs
• Pooling smooths out individual

PROs
• Independence of operation





Provides redundancy
Cleaning
Maintenance
Validation

•

CONs
• Interruption/shutdown/change to

CONs
• Increased downstream hardware

individual bioreactor(s) stream or
change to approved downstream
process may/would require long
validation/approval cycle

and operation costs
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Option 2 Selected

•

Process Validation Considerations
 Validation strategy
• Three independent campaigns of integrated unit
(if Option 1, three independent campaigns of 1st
bioreactor, then one campaign for 2nd bioreactor and
one campaign for 3rd)
• Total campaign cycle time

 Cleaning validation – need to clean before/after
three campaign runs
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Option 2 ‐ Upstream Campaign Time
Upstream Steps
Inoculum build‐up – 1 wks.
1st bioreactor production
2nd bioreactor – 3 wks. offset
3rd bioreactor – 3 wks. offset
1st bioreactor stopped – 3 mo.

Total upstream cycle time for
commercial process:
almost 5 months
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•
•
•
•
•
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Option 2 ‐ Downstream Campaign Time
Downstream Steps
•
•
•
•

3+ purification steps
Validated hold times of 1‐12
months
Typical downstream cycle time
of 8 weeks
Can accelerate to 4 weeks

Column 1, pooled harvests

Column 2, pooled column 1 eluants

Column n, pooled column 2 eluants

Drug substance
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Extensive analytical characterization

Validation Process Campaign Time Reality
Total of Campaign Upstream and
Downstream Cycles
• Typical upstream cycle time of almost 5 months
• Accelerated downstream cycle time of about 1 month
• Therefore total campaign process cycle time of almost
6 months for validation process
• For 3 campaigns, complete process validation over 18
months

© NSF 2015 Intl.

16

Product Grows – Add Additional Capacity
Company needs to increase commercial capacity and
decides to add 2 more continuous bioreactors
 Need to add downstream capacity minimally at
step 1
 Review options to expand and resulting validation,
regulatory, and operational considerations
• Comparability studies needed
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Staggered 3
weeks

Option 2

Clarification

Comparison
Option 2 – Shared Downstream

Option 1 – Two Parallel Streams
PROs

PROs
• Represents likely future commercial

• Provides some redundancy
• Independence of operation

•

 Cleaning
 Maintenance
 Validation

•

CONs

CONs
• Interruption/shutdown/change to

• Validation of not only new
•

upstream but also of new
downstream
Increased downstream hardware
and operation cost
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production (integrated)
Pooling smooths out individual
bioreactor production output and
product consistency
Savings on downstream hardware and
operations cost

individual bioreactor(s) stream or
change to approved downstream
process may/would require long
validation/approval cycle
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Option 2 Selected

•

Process Validation Considerations
 Family approach of added bioreactors
• One independent campaign of each upstream bioreactor
purified with commercial validated downstream process
• (if Option 1, three independent campaigns of new parallel
bioreactor/downstream stream)
• Blend or no blending with validated commercial upstream
• Risk of exposing validated downstream units to
unapproved process material
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Option 2 Selected

•

Process Validation Considerations
 Blend or Not‐to‐Blend with validated commercial stream
• Blend option represents future commercial operations
• Whereas not‐to‐blend option does not representative
final commercial operations
– Does avoid 1:5 dilutive effect of blending
– Therefore more rigorous comparison of new bioreactor
output vs. commercial
– Preferred by FDA and EMA
– As a result, downstream operation toggles between
commercial and validation runs
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Option 2 Selected

•

Process Validation Considerations
 Impact of exposing validated downstream units to
unapproved process material – risk assessment
• Cleaning validation developed for commercial
product
• Family bioreactor should produce similar and
comparable product and impurity profile
• Minimal risk
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Conclusions
•
•
•
•
•

Batch definition not hurdle for continuous processes with FDA
With new approaches and emerging technologies, engage
FDA early and often
Whenever dealing with legacy unique processes or products,
embrace (re)education of new agency reviewers or agency in
general
In some cases of hybrid continuous upstream manufacturing,
long production cycles valuable but with validation
consequences
In choosing between parallel processing streams or combined
processing streams, consider validation cycles for lifecycle
management
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Questions?
Contact Information:
Andy Papas
apapas@nsf.org
Cell: 202‐320‐2544
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